Free Trial
NASDAQ:EVOK

Evoke Pharma Q1 2025 Earnings Report

Evoke Pharma logo
$5.44 +0.11 (+2.06%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$5.54 +0.11 (+1.93%)
As of 08/8/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evoke Pharma EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.33
Beat/Miss
Missed by -$0.18
One Year Ago EPS
N/A

Evoke Pharma Revenue Results

Actual Revenue
$3.08 million
Expected Revenue
$3.32 million
Beat/Miss
Missed by -$236.00 thousand
YoY Revenue Growth
N/A

Evoke Pharma Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Evoke Pharma's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Evoke Pharma Earnings Headlines

Evoke Pharma (EVOK) to Release Quarterly Earnings on Tuesday
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Evoke Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evoke Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evoke Pharma and other key companies, straight to your email.

About Evoke Pharma

Evoke Pharma (NASDAQ:EVOK), a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

View Evoke Pharma Profile

More Earnings Resources from MarketBeat